UK markets closed

Novozymes A/S (NVZMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
58.75+0.81 (+1.40%)
As of 09:30AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close57.94
Open58.75
BidN/A x N/A
AskN/A x N/A
Day's range58.75 - 58.75
52-week range38.16 - 82.30
Volume6
Avg. volume1,303
Market cap16.703B
Beta (5Y monthly)0.39
PE ratio (TTM)33.96
EPS (TTM)1.73
Earnings dateN/A
Forward dividend & yield0.82 (1.41%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Globe Newswire

    As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

    Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S

  • Globe Newswire

    Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

    COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt

  • Globe Newswire

    Novozymes confirms upgraded guidance by strong start to Q4

    Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o